Abstract
RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW
Original language | English |
---|---|
Pages (from-to) | 708-720 |
Journal | Theranostics |
Volume | 4 |
Issue number | 7 |
DOIs | |
State | Published - Apr 2014 |